Publications by authors named "Ola Dale"

Claim this Profile

Mentions over time

Mentions by platform

Video Views

125

Total Likes

29

Extended Reach

71,009

Social Features

19
T
Take-Home Naloxone for the Emergency Interim Management of Opioid Overdose: The Public Health Application of an Emergency Medicine.
John Strang, Rebecca McDonald, Gabrielle Campbell, Louisa Degenhardt, Suzanne Nielsen, Alison Ritter, Ola Dale

September 2019

Videos about Article: user user

2 2 17 6

View All Article and Social Media Activity
P
Pharmacokinetics of subcutaneous and intravenous bolus doses of morphine in palliative care cancer patients receiving infusion of morphine: A pharmacokinetic substudy of a randomized controlled trial.
Eva Gravdahl, Ola Dale, Jūratė Šaltytė Benth, Siri Steine, Knut Magne Augestad

Br J Clin Pharmacol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nitazenes: review of comparative pharmacology and antagonist action.
Marcus Stangeland, Ola Dale, Arne Kristian Skulberg

Clin Toxicol (Phila)· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Heightened mortality risk after a non-fatal opioid overdose: Risk factors for mortality in the week following emergency treatment.
Desiree Eide, Linn Gjersing, Aksel Wüsthoff Danielsen, Arne Kristian Skulberg, Ola Dale

Addiction· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetic and neuroimmune pharmacogenetic impacts on slow-release morphine cancer pain control and adverse effects.
Daniel T Barratt, Pål Klepstad, Ola Dale, Stein Kaasa, Andrew A Somogyi

Pharmacogenomics J· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Not Available].
Arne Kristian Skulberg, Fridtjof Heyerdahl, Ola Dale, Desiree Eide

Tidsskr Nor Laegeforen· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical Pharmacokinetics and Pharmacodynamics of Naloxone.
Teijo I Saari, John Strang, Ola Dale

Clin Pharmacokinet· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Naloxone administration-no balance without titration.
Arne Kristian Skulberg, Ida Tylleskär, Ola Dale

Addiction· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of intranasal and intramuscular naloxone in opioid overdoses managed by ambulance staff: a double-dummy, randomised, controlled trial.
Arne Kristian Skulberg, Ida Tylleskär, Morten Valberg, Anne-Cathrine Braarud, Jostein Dale, Ola Dale

Addiction· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetic considerations for community-based dosing of nasal naloxone in opioid overdose in adults.
Ola Dale

Expert Opin Drug Metab Toxicol· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Clinical Description of Chronic Pain in a General Population Using ICD-10 and ICD-11 (The HUNT Pain Examination Study).
Petter C Borchgrevink, Mari Glette, Astrid Woodhouse, Stephen Butler, Tormod Landmark, Ola Dale

J Pain· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The pharmacokinetic interaction between nasally administered naloxone and the opioid remifentanil in human volunteers.
Ida Tylleskar, Sissel Skarra, Arne Kristian Skulberg, Ola Dale

Eur J Clin Pharmacol· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Intranasal Naloxone Administration.
Arne K Skulberg, Ida Tylleskar, Ola Dale

N Engl J Med· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
European survey on national harmonization in clinical research.
Annette Magnin, Valentina Cabral Iversen, Gonzalo Calvo, Beata Čečetková, Ola Dale

Learn Health Syst· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
NTNU intranasal naloxone trial (NINA-1) study protocol for a double-blind, double-dummy, non-inferiority randomised controlled trial comparing intranasal 1.4 mg to intramuscular 0.8 mg naloxone for prehospital use.
Arne Kristian Skulberg, Ida Tylleskär, Anne-Cathrine Braarud, Jostein Dale, Fridtjof Heyerdahl, Ola Dale

BMJ Open· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prehospital naloxone administration - what influences choice of dose and route of administration?
Ida Tylleskar, Linn Gjersing, Lars Petter Bjørnsen, Anne-Cathrine Braarud, Fridtjof Heyerdahl, Ola Dale

BMC Emerg Med· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Ambulance-attended opioid overdoses: An examination into overdose locations and the role of a safe injection facility.
Desiree Madah-Amiri, Arne Kristian Skulberg, Anne-Cathrine Braarud, Ola Dale, Fridtjof Heyerdahl

Subst Abus· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Naloxone nasal spray - bioavailability and absorption pattern in a phase 1 study.
Ida Tylleskar, Arne Kristian Skulberg, Turid Nilsen, Sissel Skarra, Ola Dale

Tidsskr Nor Laegeforen· September 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics of a novel, approved, 1.4-mg intranasal naloxone formulation for reversal of opioid overdose-a randomized controlled trial.
Arne Kristian Skulberg, Anders Åsberg, Hasse Zare Khiabani, Hilde Røstad, Ida Tylleskar, Ola Dale

Addiction· May 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacodynamics and arteriovenous difference of intravenous naloxone in healthy volunteers exposed to remifentanil.
Ida Tylleskar, Arne Kristian Skulberg, Sissel Skarra, Turid Nilsen, Ola Dale

Eur J Clin Pharmacol· December 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics and -dynamics of intramuscular and intranasal naloxone: an explorative study in healthy volunteers.
Arne Kristian Skulberg, Ida Tylleskar, Turid Nilsen, Sissel Skarra, Øyvind Salvesen, Ola Dale

Eur J Clin Pharmacol· July 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Doctors who harass].
Ola Dale

Tidsskr Nor Laegeforen· May 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
International patent applications for non-injectable naloxone for opioid overdose reversal: Exploratory search and retrieve analysis of the PatentScope database.
Rebecca McDonald, Øyvind Danielsson Glende, Ola Dale, John Strang

Drug Alcohol Rev· February 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Does the editorial committee still have a role to play?
Ola Dale, Erik Magnus Berntsen, Mette Brekke, Anne Høye, Ole-Erik Iversen

Tidsskr Nor Laegeforen· September 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Chronic pain: One year prevalence and associated characteristics (the HUNT pain study).
Tormod Landmark, Pål Romundstad, Ola Dale, Petter C Borchgrevink, Lars Vatten

Scand J Pain· October 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis